Reforgene named a GHRC 2020 Best Employer brand
On December 11, 2020, the annual HR "Oscar", the "GHRC 2020 China Human Resources Sirius Awards" ceremony, was held as scheduled. This year's Sirius Awards, themed "Digital HR: Looking Back from the Future", selected the best practices of enterprises in HR digitalization, and also embodied a microcosm of the current development of enterprise HR digitalization. It is understood that this edition of the GHRC 2020 China Human Resources Sirius Awards lasted 35 days, attracting 1,562 enterprises from 10 provinces and cities to participate, with more than 100,000 votes cast and more than one hundred HR management cases collected from various industries, an unprecedented grand occasion.
As a preclinical-stage gene editing drug high-tech enterprise in China, Reforgene is dedicated to the development of curative medicines rather than iterative development of conventional drugs, and is a typical representative of China's innovation in the biomedical field. In the past two years, it has attracted a group of outstanding scientists and pharmaceutical professionals from home and abroad, and is also a representative of the emerging force in the technology community. With its distinctive enterprise culture of innovation and openness, it won this Best Employer award and is one of the few early-stage enterprises to do so. Other recipients of this honor included Walmart (China) Investment Co., Ltd., JD.com, So-Young Technology, CodeMao and other medium and large technology enterprises.
It is worth noting that this edition's jury was the most prestigious in history, composed of 30 Fortune Global 500 executives and HR mentors from prestigious universities, ensuring the authority and professionalism of the award. The selection criteria were also extremely strict, evaluating multiple dimensions such as the use, construction and exploration of HR and recruitment management informatization systems, combined with the recommendations of the expert jury. The selection experts included Sun Jianmin, Professor at the School of Labor and Human Resources of Renmin University of China; Tang Kuang, Party Secretary/Professor of the same school; Caroline, former HR General Manager of Standard Chartered Bank China; Lewis, HR Director of the Digital Services Business Group of Ericsson Northeast Asia; Huang Kun, HR Head of Canada Goose China; Qi Yanping, Deputy Director of the HR Management Department of BAIC Group; Zhang Wei, CHRO of Semir; Liao Bin, HRVP of Li-Ning, and others.
About the China Human Resources Sirius Awards
The GHRC 2020 China Human Resources Sirius Awards is a highly followed annual selection program in China's HR industry, organized by Beijing Cirius Technology Co., Ltd., dedicated to promoting the development of the HR industry and continuously providing value to society. Taking "the brightest star in the night sky" as its beautiful symbol, it selects quality enterprises, teams and individuals in digitalization and informatization practices across all industries and fields including the internet, retail, education, pharmaceuticals, e-commerce and manufacturing, promoting the development and progress of China's HR technology, and is therefore known as the "Oscar" of the HR field.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.